Filipe Pereira , Ervin Ascic , Fritiof Åkerström , Malavika Sreekumar Nair , André Rosa , Ilia Kurochkin , Olga Zimmermannova , Xavier Catena , Nadezhda Rotankova , Charlotte Veser , Michal Rudnik , Tommaso Ballocci , Tiffany Schärer , Xiaoli Huang , Emilie Renaud , Marta Velasco Santiago , Özcan Met , David Askmyr , Malin Lindstedt , Lennart Greiff , Fábio Rosa
{"title":"2026 - 基于树突状细胞体内重编程的癌症免疫疗法模式","authors":"Filipe Pereira , Ervin Ascic , Fritiof Åkerström , Malavika Sreekumar Nair , André Rosa , Ilia Kurochkin , Olga Zimmermannova , Xavier Catena , Nadezhda Rotankova , Charlotte Veser , Michal Rudnik , Tommaso Ballocci , Tiffany Schärer , Xiaoli Huang , Emilie Renaud , Marta Velasco Santiago , Özcan Met , David Askmyr , Malin Lindstedt , Lennart Greiff , Fábio Rosa","doi":"10.1016/j.exphem.2024.104584","DOIUrl":null,"url":null,"abstract":"<div><p>Immunotherapy leads to long-term survival of cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells, induced complete tumor regressions, and established long-term systemic immunity in different mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for first-in-human trials and other applications of immune cell reprogramming in vivo.</p></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"137 ","pages":"Article 104584"},"PeriodicalIF":2.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0301472X24004430/pdfft?md5=1606df2fe6cbdfc4e0de830e903f5f31&pid=1-s2.0-S0301472X24004430-main.pdf","citationCount":"0","resultStr":"{\"title\":\"2026 – A CANCER IMMUNOTHERAPY MODALITY BASED ON DENDRITIC CELL REPROGRAMMING IN VIVO\",\"authors\":\"Filipe Pereira , Ervin Ascic , Fritiof Åkerström , Malavika Sreekumar Nair , André Rosa , Ilia Kurochkin , Olga Zimmermannova , Xavier Catena , Nadezhda Rotankova , Charlotte Veser , Michal Rudnik , Tommaso Ballocci , Tiffany Schärer , Xiaoli Huang , Emilie Renaud , Marta Velasco Santiago , Özcan Met , David Askmyr , Malin Lindstedt , Lennart Greiff , Fábio Rosa\",\"doi\":\"10.1016/j.exphem.2024.104584\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Immunotherapy leads to long-term survival of cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells, induced complete tumor regressions, and established long-term systemic immunity in different mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for first-in-human trials and other applications of immune cell reprogramming in vivo.</p></div>\",\"PeriodicalId\":12202,\"journal\":{\"name\":\"Experimental hematology\",\"volume\":\"137 \",\"pages\":\"Article 104584\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0301472X24004430/pdfft?md5=1606df2fe6cbdfc4e0de830e903f5f31&pid=1-s2.0-S0301472X24004430-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0301472X24004430\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0301472X24004430","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
2026 – A CANCER IMMUNOTHERAPY MODALITY BASED ON DENDRITIC CELL REPROGRAMMING IN VIVO
Immunotherapy leads to long-term survival of cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells, induced complete tumor regressions, and established long-term systemic immunity in different mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for first-in-human trials and other applications of immune cell reprogramming in vivo.
期刊介绍：
Experimental Hematology publishes new findings, methodologies, reviews and perspectives in all areas of hematology and immune cell formation on a monthly basis that may include Special Issues on particular topics of current interest. The overall goal is to report new insights into how normal blood cells are produced, how their production is normally regulated, mechanisms that contribute to hematological diseases and new approaches to their treatment. Specific topics may include relevant developmental and aging processes, stem cell biology, analyses of intrinsic and extrinsic regulatory mechanisms, in vitro behavior of primary cells, clonal tracking, molecular and omics analyses, metabolism, epigenetics, bioengineering approaches, studies in model organisms, novel clinical observations, transplantation biology and new therapeutic avenues.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
